Short answer
Evolent Health, Inc. (EVH) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $725M (up 51.3% year over year) with net income of −$24M.
Q3 2026 key financials · XBRL
- Revenue
- $725M
- +51.3% YoY · +11.2% QoQ
- Net income
- −$24M
- −13.0% YoY · +16.9% QoQ
- Operating margin
- -0.9%
- EPS (diluted)
- −$0.21
- +12.5% YoY · +16.0% QoQ
Source: XBRL data from the Evolent Health, Inc. (EVH) Q3 2026 10-Q on SEC EDGAR. USD.
Evolent Health, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $725.4M, up 51.3% YoY from $479.5M, driven by new Performance Suite contracts
- Performance Suite revenue $564.3M vs $286.9M; worst line Specialty Technology and Services, $72.8M vs $93.3M
- MER 93.0% vs 85.0%; cost of revenue 87.8% vs 79.2% of revenue
- Operating loss $6.2M vs $0.9M; SG&A margin 10.1% vs 16.2%
- Cash $148.3M plus restricted cash $7.6M; operating cash flow $16.1M vs $(10.0)M YoY
- Headwinds: higher cancer and cardiovascular treatment costs, Medicaid and Exchange membership declines ahead
Risk Factors
- No material risk-factor changes reported for quarter ended September 30, 2026
- Carried-forward risks remain those disclosed in Evolent Health’s 2025 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Evolent Health, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.